Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2012, No. 3


Vargas RÁG, Ramírez LAN, Medina VME
Nuevos anticoagulantes: dabigatrán, rivaroxabán y apixabán
Gac Med Mex 2012; 148 (3)

Idioma: Español
Referencias bibliográficas: 37
Paginas: 257-264
Archivo PDF: 90.79 Kb.


Texto completo




RESUMEN

Hasta hoy, los medicamentos más utilizados en nuestras clínicas de anticoagulación son la acenocumarina y la warfarina, que pertenecen a la categoría de antagonistas de la vitamina K (AVK). Tienen cerca de 70 años de uso en la clínica, con probada eficacia para distintas enfermedades trombóticas, aunque también con conocidos problemas derivados de su variabilidad e interacciones farmacológicas y dietéticas. En tromboprofilaxis hospitalaria, la enoxaparina es el anticoagulante más utilizado, una heparina de bajo peso molecular (HBPM). Una nueva generación de anticoagulantes está disponible, los inhibidores directos de la trombina (como dabigatrán) y del factor Xa (rivaroxabán y apixabán), con evidentes ventajas sobre los anticoagulantes convencionales. En este artículo se resume lo publicado hasta el momento para estos nuevos antitrombóticos.


Palabras clave: Anticoagulantes, Dabigatrán, Rivaroxabán, Apixabán.


REFERENCIAS

  1. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.

  2. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther. 2007;45(6):335-44.

  3. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.

  4. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949-56.

  5. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721-9.

  6. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-85.

  7. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1-9.

  8. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-75.

  9. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-9.

  10. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86.

  11. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-80.

  12. Kwong LM. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag. 2011;7:461-6.

  13. Aalbers J. FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery. Cardiovasc J Afr. 2011;22(4):218.

  14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.

  15. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717): 807-15.

  16. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramírez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-98.

  17. Watson J, Whiteside G, Perry C. Apixaban: first global approval. Drugs. 2011;71(15):2079-89.

  18. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.

  19. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.

  20. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEINExtension study). Expert Rev Cardiovasc Ther. 2011;9(7):841-4.

  21. Rosenberg DJ, Ansell J. Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications. Evid Based Med. 2011;16(5):139-40.

  22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.

  23. Ingelmo C, Wazni O. Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: warfarin versus dabigatran. Curr Cardiol Rep. 2011;13(5):357-60.

  24. Wartak SA, Bartholomew JR. Dabigatran: Will it change clinical practice? Cleve Clin J Med. 2011;78(10):657-64.

  25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.

  26. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.

  27. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 981-92.

  28. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study. Circ J. 2011;75(8):1852-9.

  29. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 ;32(22): 2781-9.

  30. Alexander D, Jeremias A. Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011;20(6):849-57.

  31. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.

  32. Maegdefessel L, Linde T, Krapiec F, et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res. 2010;126(3):e196-200.

  33. McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141(6):1410-6.

  34. Kaeberich A, Reindl I, Raaz U, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32(4):417-25.

  35. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N Engl J Med. 2011;365(23):2167-77.

  36. Battinelli EM. Reversal of new oral anticoagulants. Circulation. 2011;124(14):1508-10.

  37. Spahn DR, Korte W. Novel Oral Anticoagulants: New Challenges for Anesthesiologists in Bleeding Patients. Anesthesiology. 2011. [Epub ahead of print]



>Revistas >Gaceta Médica de México >Año2012, No. 3
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019